PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer

Phase 3 trial: PSMA-PET-CT may help some high-risk men avoid prostate biopsy

A phase 3 clinical trial published in The Lancet Oncology suggests that PSMA-PET-CT imaging may help determine which men at high clinical ri

Study: Imaging scans detect prostate cancer progression missed by stable PSA levels

A new analysis led by researchers at Weill Cornell Medicine and Duke University, published in the Journal of Clinical Oncology, found that a

NHS to offer precision radiotherapy for prostate cancer, cutting treatment from 20 to 5 sessions

The NHS in England is rolling out precision radiotherapy (stereotactic ablative radiotherapy/SABR) for prostate cancer, reducing treatment s

Imaging Scans Detect Prostate Cancer Progression Despite Stable PSA Levels – Weill Cornell Medicine

GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment

GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized

NHS England to offer targeted SABR radiotherapy for early prostate cancer, reducing treatment sessions from 20 to 5

NHS England will offer stereotactic radiotherapy (SABR) to thousands of men with early prostate cancer across all 48 radiotherapy centres wi